Security
BCTG Acquisition Corp. Common Stock · BCTG
BCTGNASDAQCommon stockHistorical · closed Aug 10, 2021CIK 1819133Updated Nov 3, 2026
Name history
BCTG Acquisition Corp. · through Aug 9, 2021
Current security for this SEC filerTNGX · NASDAQ
BCTG price & chart
Historical security
This listing closed Aug 10, 2021. Live provider charts are shown only for current listings.
Current security: TNGX
About the company
Tango Therapeutics is a clinical-stage biotechnology company dedicated to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer. Using an approach that focuses on genetic vulnerabilities in cancer, Tango is pursuing PRMT5-targeted therapies designed to address pancreatic and other forms of cancer while sparing healthy normal tissues.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 210,136,000Source | 352,415,000Source | 1,073,880,000Source | 237,890,000Source | 381,453,000Source | 435,792,000Source | 274,306,000Source | 406,222,000Source | 398,690,000Source | 316,492,000Source | 402,567,000Source | 436,470,000Source |
| Property, Plant and Equipment, NetUSD | 7,346,000Source | 8,590,000Source | 6,094,000Source | 7,786,000Source | 9,095,000Source | 6,381,000Source | 7,539,000Source | 9,522,000Source | 6,868,000Source | 8,102,000Source | 9,908,000Source | 10,884,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 58,338,000Source | 53,148,000Source | 345,558,000Source | 39,272,000Source | 51,566,000Source | 157,828,000Source | 58,432,000Source | 61,163,000Source | 112,279,000Source | 69,530,000Source | 66,385,000Source | 59,968,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 2,000,000Source |
| Assets, CurrentUSD | 163,779,000Source | 300,815,000Source | 1,031,671,000Source | 190,100,000Source | 328,410,000Source | 392,327,000Source | 224,930,000Source | 352,036,000Source | 353,756,000Source | 266,343,000Source | 346,538,000Source | 375,272,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 10,540,000Source | 7,537,000Source | 17,681,000Source | 8,887,000Source | 6,299,000Source | 12,488,000Source | 7,778,000Source | 8,437,000Source | 10,190,000Source | 8,426,000Source | 8,797,000Source | 6,572,000Source |
| Operating Lease, Right-of-Use AssetUSD | 36,582,000Source | 40,430,000Source | 33,664,000Source | 37,555,000Source | 41,371,000Source | 34,652,000Source | 39,697,000Source | 42,086,000Source | 35,624,000Source | 39,476,000Source | 43,508,000Source | 46,886,000Source |
| Other Assets, NoncurrentUSD | 290,000Source | 13,000Source | 312,000Source | 310,000Source | 10,000Source | 293,000Source | 1,000Source | 11,000Source | 303,000Source | 4,000Source | 46,000Source | 5,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 50,105,000Source | 123,245,000Source | 49,348,000Source | 102,936,000Source | 133,780,000Source | 44,286,000Source | 107,550,000Source | 141,770,000Source | 52,511,000Source | 116,975,000Source | 149,459,000Source | 186,994,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 112,000Source | 107,000Source | 168,000Source | 111,000Source | 107,000Source | 144,000Source | 108,000Source | 107,000Source | 136,000Source | 108,000Source | 102,000Source | 88,000Source |
| Additional Paid in CapitalUSD | 724,201,000Source | 692,201,000Source | 1,729,004,000Source | 715,036,000Source | 682,621,000Source | 1,040,143,000Source | 707,888,000Source | 673,772,000Source | 948,971,000Source | 700,631,000Source | 624,076,000Source | 522,605,000Source |
| Retained Earnings (Accumulated Deficit)USD | -564,403,000Source | -463,888,000Source | -704,007,000Source | -580,287,000Source | -434,721,000Source | -648,666,000Source | -541,434,000Source | -409,170,000Source | -603,152,000Source | -501,558,000Source | -371,256,000Source | -269,512,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 121,000Source | 750,000Source | -633,000Source | 94,000Source | -334,000Source | -115,000Source | 194,000Source | -257,000Source | 224,000Source | 336,000Source | 186,000Source | -3,705,000Source |
| Stockholders' Equity Attributable to ParentUSD | 160,031,000Source | 229,170,000Source | 1,024,532,000Source | 134,954,000Source | 247,673,000Source | 391,506,000Source | 166,756,000Source | 264,452,000Source | 346,179,000Source | 199,517,000Source | 253,108,000Source | 249,476,000Source |
| Liabilities and EquityUSD | 210,136,000Source | 352,415,000Source | 1,073,880,000Source | 237,890,000Source | 381,453,000Source | 435,792,000Source | 274,306,000Source | 406,222,000Source | 398,690,000Source | 316,492,000Source | 402,567,000Source | 436,470,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,444,000Source | 37,583,000Source | 20,299,000Source | 40,025,000Source | 43,868,000Source | 14,330,000Source | 35,917,000Source | 42,789,000Source | 21,679,000Source | 38,170,000Source | 45,938,000Source | 55,545,000Source |
| Operating Lease, Liability, CurrentUSD | 3,102,000Source | 2,863,000Source | 2,943,000Source | 2,534,000Source | 2,364,000Source | 2,832,000Source | 2,824,000Source | 2,066,000Source | 2,738,000Source | 2,454,000Source | 2,082,000Source | 1,770,000Source |
| Accounts Payable, CurrentUSD | 2,229,000Source | 4,112,000Source | 1,810,000Source | 2,607,000Source | 1,062,000Source | 2,430,000Source | 3,239,000Source | 3,898,000Source | 1,182,000Source | 1,601,000Source | 2,785,000Source | 4,453,000Source |
| Operating Lease, Liability, NoncurrentUSD | 31,661,000Source | 34,763,000Source | 29,049,000Source | 32,474,000Source | 35,473,000Source | 29,956,000Source | 34,122,000Source | 36,169,000Source | 30,832,000Source | 34,039,000Source | 36,838,000Source | 39,361,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 152,800,000Source | — | 1,000,000,000Source | 180,800,000Source | — | 379,800,000Source | 216,700,000Source | — | 343,100,000Source | 257,900,000Source | — | — |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -45,514,000Source | -39,876,000Source | -101,594,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,797,000Source | 7,255,000Source | 26,430,000Source | 28,897,000Source | 19,079,000Source | 14,230,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | -2,000,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -44,360,000Source | -41,697,000Source | -138,886,000Source | -131,501,000Source | -117,982,000Source | -109,080,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 9,635,000Source | 30,597,000Source | -40,865,000Source | 86,126,000Source | 41,426,000Source | 26,399,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | -2,000Source | 51,000Source | 1,048,000Source | 754,000Source | 1,526,000Source | 7,692,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 79,846,000Source | 2,000Source | 222,500,000Source | 47,664,000Source | 82,406,000Source | 1,615,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 45,121,000Source | -11,098,000Source | 42,749,000Source | 2,289,000Source | 5,850,000Source | -81,066,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 60,905,000Source | 55,715,000Source | 347,697,000Source | 41,839,000Source | 159,967,000Source | 60,999,000Source | 114,846,000Source | 72,097,000Source | 69,808,000Source | 63,958,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 12,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,625,000Source | 7,178,000Source | 16,892,000Source | 6,570,000Source | 10,797,000Source | 7,255,000Source | 26,430,000Source | 28,897,000Source | 19,079,000Source | 14,230,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 152,800,000Source | — | 1,000,000,000Source | 180,800,000Source | 379,800,000Source | 216,700,000Source | 343,100,000Source | 257,900,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 463,000Source | 622,000Source | 2,281,000Source | 2,499,000Source | 2,415,000Source | 1,608,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 8,924,000Source | 11,222,000Source | 22,586,000Source | 11,341,000Source | 15,235,000Source | 11,480,000Source | 41,508,000Source | 43,746,000Source | 35,502,000Source | 30,025,000Source |
| Income Tax Expense (Benefit)USD | — | — | -10,000Source | 54,000Source | 1,000Source | 35,000Source | 1,000Source | 34,000Source | 4,000Source | 208,000Source | 134,000Source | 54,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 27,000Source | 1,084,000Source | -518,000Source | -100,000Source | -339,000Source | -142,000Source | -112,000Source | 150,000Source | 3,891,000Source | -2,940,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 15,884,000Source | -29,167,000Source | -55,341,000Source | -38,853,000Source | -45,514,000Source | -39,876,000Source | -101,594,000Source | -130,302,000Source | -101,744,000Source | -108,176,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,802,000Source | 3,765,000Source | 4,445,000Source | 2,149,000Source | 3,256,000Source | 2,688,000Source | 9,699,000Source | 15,501,000Source | 12,563,000Source | 2,949,000Source |
| Operating ExpensesUSD | — | — | 39,739,000Source | 44,485,000Source | 59,785,000Source | 44,148,000Source | 48,769,000Source | 47,922,000Source | 173,673,000Source | 187,664,000Source | 150,700,000Source | 135,931,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 705,000Source | 1,956,000Source | 722,000Source | 910,000Source | 1,079,000Source | 1,074,000Source | 4,069,000Source | 7,611,000Source | 5,944,000Source | 1,493,000Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | — | — | 689,000Source | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 53,811,000Source | 11,607,000Source | 0Source | 3,181,000Source | 0Source | 5,392,000Source | 62,384,000Source | 42,069,000Source | 36,527,000Source | 24,860,000Source |
| Operating Income (Loss)USD | — | — | 14,072,000Source | -32,878,000Source | -59,785,000Source | -40,967,000Source | -48,769,000Source | -42,530,000Source | -111,289,000Source | -145,595,000Source | -114,173,000Source | -111,071,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 705,000Source | 1,956,000Source | 722,000Source | 910,000Source | 1,079,000Source | 1,074,000Source | 4,069,000Source | 7,611,000Source | 5,944,000Source | 1,493,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 15,874,000Source | -29,113,000Source | -55,340,000Source | -38,818,000Source | -45,513,000Source | -39,842,000Source | -101,590,000Source | -130,094,000Source | -101,610,000Source | -108,122,000Source |
| Income Tax Expense (Benefit)USD | — | — | -10,000Source | 54,000Source | 1,000Source | 35,000Source | 1,000Source | 34,000Source | 4,000Source | 208,000Source | 134,000Source | 54,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 15,884,000Source | -29,167,000Source | -55,341,000Source | -38,853,000Source | -45,514,000Source | -39,876,000Source | -101,594,000Source | -130,302,000Source | -101,744,000Source | -108,176,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.14Source | -0.27Source | -0.37Source | -0.35Source | -0.32Source | -0.36Source | -0.87Source | -1.19Source | -1.08Source | -1.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.13Source | -0.27Source | -0.37Source | -0.35Source | -0.32Source | -0.36Source | -0.87Source | -1.19Source | -1.08Source | -1.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 110,966,345Source | 108,507,390Source | 149,875,939Source | 110,540,836Source | 143,576,292Source | 110,301,256Source | 116,166,187Source | 109,226,731Source | 94,572,448Source | 87,820,037Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 117,782,074Source | 108,507,390Source | 149,875,939Source | 110,540,836Source | 143,576,292Source | 110,301,256Source | 116,166,187Source | 109,226,731Source | 94,572,448Source | 87,820,037Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 8,924,000Source | 11,222,000Source | 22,586,000Source | 11,341,000Source | 15,235,000Source | 11,480,000Source | 41,508,000Source | 43,746,000Source | 35,502,000Source | 30,025,000Source |
| Interest Income (Expense), NetUSD | — | — | 1,097,000Source | 1,809,000Source | 3,723,000Source | 1,239,000Source | 2,177,000Source | 1,614,000Source | 5,630,000Source | 7,890,000Source | 6,619,000Source | 1,456,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,802,000Source | 3,765,000Source | 4,445,000Source | 2,149,000Source | 3,256,000Source | 2,688,000Source | 9,699,000Source | 15,501,000Source | 12,563,000Source | 2,949,000Source |
| Operating ExpensesUSD | — | — | 39,739,000Source | 44,485,000Source | 59,785,000Source | 44,148,000Source | 48,769,000Source | 47,922,000Source | 173,673,000Source | 187,664,000Source | 150,700,000Source | 135,931,000Source |
| Research and Development ExpenseUSD | — | — | 30,815,000Source | 33,263,000Source | 37,199,000Source | 32,807,000Source | 33,534,000Source | 36,442,000Source | 132,165,000Source | 143,918,000Source | 115,198,000Source | 105,906,000Source |
Filing attachments
d151613dex991.htm · 8-K · 2026-10-23
Exhibit 99.1 Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib Vopimetostat combinations with RAS(ON) inhibitors daraxonrasib or zoldonrasib continued to be generally well-tolerated Registrationa…
Read attachment ↗d151613dex992.htm · 8-K · 2026-10-23
Exhibit 99.2 PDAC Investor Presentation October 23, 2026 Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics, Inc. (Tango) and members of the Tango senior management team. Forward-looking statements are not p…
Read attachment ↗tngx-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 tngx-ex99_1.htm EX-99.1 EX-99.1 Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of vopimetostat + RAS(ON) inhibitors in pancreatic cancer to be presented at 2026 ESMO Congress Key appointments further position Company for l…
Read attachment ↗d215768dex991.htm · 8-K/A · 2026-08-07
EX-99.1 3 d215768dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tango Therapeutics Announces Executive Chair Transition BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits.…
Read attachment ↗d79260dex991.htm · 8-K · 2026-06-23
EX-99.1 2 d79260dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tango Therapeutics Appoints Robert Azelby to Board of Directors June 22, 2026 BOSTON, June 22, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience ac…
Read attachment ↗d81492dex41.htm · 8-K · 2026-06-10
EX-4.1 3 d81492dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. TANGO THERAP…
Read attachment ↗